Scientists at the UK’s University of Oxford said Tuesday they’ve found that a low-cost, common drug significantly reduced coronavirus-related deaths in a 6,000-patient trial. Dexamethasone, a steroid, cut down deaths in patients receiving ventilation by one-third, they said. In patients getting oxygen treatment, it reduced deaths by one-fifth.
The drug didn’t appear to help patients who aren’t receiving respiratory support.
Britain’s National Health Service will work the drug into its standard COVID-19 treatment starting Tuesday, according to UK health secretary Matt Hancock. The government has 200,000 doses available now, having stockpiled it for months.
“The survival benefit is clear and large in those patients who are sick enough to require oxygen treatment, so dexamethasone should now become standard of care in these patients,” Professor Peter Horby, one of the lead researchers, said in a release. “Dexamethasone is inexpensive, on the shelf, and can be used immediately to save lives worldwide.”
The information contained in this article is for educational and informational purposes only and is not intended as health or medical advice. Always consult a physician or other qualified health provider regarding any questions you may have about a medical condition or health objectives.